NL019 / Naliean Therapeutics - LARVOL DELTA

NL019: A next-generation TROP2/NECTIN4 dual-target nanobody-based ADC developed from the NanoOne™ Platform (AACR 2026) - "NL019 exemplifies the disruptive potential of NanoOne™, combining advanced molecular architecture, precision one/dual-payload conjugation, and superior tumor selectivity. Supported by strong preclinical efficacy and developability, NL019 is advancing toward first-in-human trials. Given the broad expression of TROP2 and NECTIN4 across epithelial malignancies, NL019 has the potential to establish a new generation of broad-spectrum ADC therapeutics."

ADC • First-in-human • Oncology • NECTIN4 • TACSTD2